Trial · NCT02227992
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Absolute Time to Haemostasis (TTH) | EVARREST Sealant Matrix | 4.0 | Full Range 4.0 to 117.0 | Minutes | |
| Absolute Time to Haemostasis (TTH) | SURGICEL Absorbable Hemostat (Control) | 4.0 | Full Range 4.0 to 39.0 | Minutes | |
Percentage of Participants Achieving Haemostatic Success at 4 Minutes Following Randomization With No Bleeding Requiring Treatment at the Target Bleeding Site Occurring Any Time Prior to Final Fascial Closure | EVARREST Sealant Matrix | 80.0 | 95% Confidence Interval 56.3 to 94.3 | Percentage of Participants | |
Percentage of Participants Achieving Haemostatic Success at 4 Minutes Following Randomization With No Bleeding Requiring Treatment at the Target Bleeding Site Occurring Any Time Prior to Final Fascial Closure | SURGICEL Absorbable Hemostat (Control) | 60.0 | 95% Confidence Interval 36.1 to 80.9 | Percentage of Participants | |
Percentage of Participants Achieving Haemostatic Success at 10 Minutes Following Randomization With No Bleeding Requiring Treatment at the Target Bleeding Site Occurring Any Time Prior to Final Fascial Closure | EVARREST Sealant Matrix | 95.0 | 95% Confidence Interval 75.1 to 99.9 | Percentage of Participants | |
Percentage of Participants Achieving Haemostatic Success at 10 Minutes Following Randomization With No Bleeding Requiring Treatment at the Target Bleeding Site Occurring Any Time Prior to Final Fascial Closure | SURGICEL Absorbable Hemostat (Control) | 90.0 | 95% Confidence Interval 68.3 to 98.8 | Percentage of Participants | |
| Percentage of Participants With No Re-bleeding at the Target Bleeding Site | EVARREST Sealant Matrix | 95.0 | Percentage of Participants | ||
| Percentage of Participants With No Re-bleeding at the Target Bleeding Site | SURGICEL Absorbable Hemostat (Control) | 85.0 | Percentage of Participants | ||
| Number of Participants With Adverse Events (AEs) That Were Potentially Related To Bleeding at the TBS | EVARREST Sealant Matrix | 1 | Participants | ||
| Number of Participants With Adverse Events (AEs) That Were Potentially Related To Bleeding at the TBS | SURGICEL Absorbable Hemostat (Control) | 3 | Participants | ||
| Number of Participants With AEs That Were Potentially Related To Thrombotic Events | EVARREST Sealant Matrix | 0 | Participants | ||
| Number of Participants With AEs That Were Potentially Related To Thrombotic Events | SURGICEL Absorbable Hemostat (Control) | 0 | Participants | ||
| Number of Participants Who Required Re-treatment At The Target Bleeding Site | EVARREST Sealant Matrix | 1 | Participants | ||
| Number of Participants Who Required Re-treatment At The Target Bleeding Site | SURGICEL Absorbable Hemostat (Control) | 5 | Participants | ||
| Number of Participants With Adverse Events | EVARREST Sealant Matrix | 18 | Participants | ||
| Number of Participants With Adverse Events | SURGICEL Absorbable Hemostat (Control) | 18 | Participants | ||
| Change From Baseline to Post-surgery in Haemoglobin | EVARREST Sealant Matrix | 0.0 | Full Range -56.0 to 43.0 | grams/liter (g/L) | |
| Change From Baseline to Post-surgery in Haemoglobin | SURGICEL Absorbable Hemostat (Control) | -10.0 | Full Range -150.0 to 44.0 | grams/liter (g/L) | |
| Change From Baseline to Post-surgery in Haematocrit | EVARREST Sealant Matrix | 0.0 | Full Range -0.2 to 0.1 | Liter of cells per liter of blood (L/L) | |
| Change From Baseline to Post-surgery in Haematocrit | SURGICEL Absorbable Hemostat (Control) | -0.0 | Full Range -0.1 to 0.1 | Liter of cells per liter of blood (L/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02227992/results